Core Insights - Gilead Sciences, Inc. (GILD) is enhancing its external innovation strategy through targeted acquisitions to diversify its pipeline beyond its leading HIV franchise [1] Group 1: Acquisitions and Strategic Moves - The acquisition of Ouro Medicines introduces OM336 (gamgertamig), a clinical-stage bispecific T-cell engager, to Gilead's inflammation portfolio, valued at $1.675 billion upfront with potential milestones of up to $500 million [2] - Gilead's acquisition of Arcellx for approximately $7.8 billion focuses on anitocabtagene autoleucel (anito-cel), a late-stage CAR-T therapy for relapsed or refractory multiple myeloma, with a U.S. regulatory decision expected by December 2026 [3] - The Arcellx deal allows Gilead to consolidate full economic rights to anito-cel, enhancing long-term margin potential and value capture by eliminating prior profit-sharing and royalty obligations [4] Group 2: Financial Implications and Market Position - These acquisitions indicate a strategic shift towards higher-growth therapeutic areas such as oncology and immunology, reducing reliance on HIV revenues from blockbuster products like Biktarvy and Descovy [5] - Management anticipates that the Arcellx transaction will be earnings accretive by 2028, reinforcing the long-term financial rationale for these acquisitions [5] Group 3: Competitive Landscape - Gilead faces increasing competition in the cell therapy segment, particularly from Bristol Myers (BMY) and Novartis (NVS), which have strong CAR-T therapy portfolios [6][7] - BMY's Breyanzi surpassed $1 billion in annualized sales in 2025, while NVS's Kymriah recorded sales of $381 million in 2025, down 14% from 2024 due to competitive pressures [8][9] Group 4: Stock Performance and Estimates - GILD shares have increased by 11.5% year to date, outperforming the industry growth of 1.6% [13] - GILD's shares currently trade at a price/earnings ratio of 15.4x forward earnings, higher than its mean of 11.37x but lower than the large-cap pharma industry average of 16.99x [14] - The bottom-line estimate for 2026 has risen to $8.66 from $8.63 over the past 30 days, while the estimate for 2027 has increased to $9.63 from $9.59 [15]

Core Insights - Gilead Sciences, Inc. (GILD) is facing competitive pressures in its cell therapy franchise, which includes Yescarta and Tecartus, leading to a 7% year-over-year sales decline to $1.8 billion in 2025 [1][9] - To address this decline, GILD plans to acquire Arcellx for $7.8 billion, which will enhance its control over the anito-cel therapy and streamline development and commercialization [2][4][9] Sales Performance - Sales from GILD's cell therapy unit decreased by 7% year-over-year to $1.8 billion in 2025, with Yescarta sales down 5% to $1.5 billion and Tecartus sales down 15% to $344 million [1][9] - The decline is attributed to increasing competition from both in-class and out-of-class therapies [1][9] Acquisition Strategy - GILD's acquisition of Arcellx is valued at $115 per share in cash plus a $5 contingent value right, totaling an equity value of $7.8 billion [2] - This acquisition will provide GILD full control over anito-cel, eliminating profit-sharing and enhancing long-term margin potential [4] Pipeline Developments - GILD's subsidiary, Kite, is collaborating with Arcellx to co-develop anito-cel, which has received FDA acceptance for a biologics license application as a treatment for relapsed or refractory multiple myeloma, with a decision expected in December 2026 [3][4] Competitive Landscape - GILD faces strong competition in the cell therapy market from companies like Bristol Myers (BMY) and Novartis (NVS), with BMY's Breyanzi surpassing $1 billion in annualized sales in 2025 [6][7] - NVS's Kymriah recorded sales of $381 million in 2025, reflecting a 14% decline due to competitive pressures [8] Financial Performance - GILD's shares have increased by 30.3% over the past year, outperforming the industry growth of 15.4% [11] - The current price/earnings ratio for GILD is 16.41x forward earnings, higher than its historical mean of 11.32x but lower than the large-cap pharma industry average of 17.89x [13] Earnings Estimates - The bottom-line estimate for GILD in 2026 has increased to $8.66 from $8.60, while the estimate for 2027 has risen to $9.63 from $9.33 [14]

Core Viewpoint - The article discusses the evolution and differentiation of CAR-T cell therapy, highlighting the challenges of autologous CAR-T and the emergence of allogeneic UCAR-T and in vivo CAR-T as key development directions in the industry [2][3][25]. Group 1: CAR-T Technology Development - Autologous CAR-T therapy has established clinical value but faces significant limitations such as long production cycles, high costs, and manufacturing failures [2][8]. - Allogeneic UCAR-T offers a solution to these challenges by using healthy donor cells, allowing for immediate availability, cost control, and enhanced safety [2][10]. - In vivo CAR-T, which generates CAR-T cells directly within the patient, is gaining attention for its potential to reduce treatment time and costs, although it is still in early exploration stages [3][9]. Group 2: Technical Pathways and Maturity - The CAR-T field has three distinct technical pathways: autologous CAR-T, in vivo CAR-T, and UCAR-T, each with unique advantages and limitations [6][7]. - Autologous CAR-T is commercially mature but has significant bottlenecks, while in vivo CAR-T is a hot topic but faces technical challenges and is still in early clinical exploration [8][9]. - UCAR-T is evolving through technological iterations, addressing early challenges such as immune rejection and storage issues, and is becoming a critical pathway in CAR-T development [10][13]. Group 3: UCAR-T's Technological Iteration - Early UCAR-T faced issues like immune rejection and short in vivo persistence, but advancements in gene editing technologies are overcoming these hurdles [14][15]. - Innovative strategies such as "disguise" and "counterattack" are being developed to enhance the persistence and efficacy of UCAR-T cells [15][16]. - The strategic knockout of HLA molecules is emerging as a key innovation to address immune rejection, significantly improving the clinical applicability of UCAR-T [16]. Group 4: Market Opportunities and Challenges - The field of autoimmune diseases presents a significant opportunity for UCAR-T, as it aligns well with the challenges of obtaining high-quality autologous T cells [17][19]. - Domestic companies are advancing UCAR-T therapies into clinical stages for autoimmune diseases, positioning themselves in a less competitive market compared to blood cancers [17][19]. - The safety and tolerability of UCAR-T in autoimmune patients are critical metrics for assessing its maturity and potential market success [20][21]. Group 5: Future Outlook and Value Proposition - The coexistence of autologous CAR-T, UCAR-T, and in vivo CAR-T reflects a layered approach to meet diverse clinical needs, with UCAR-T focusing on accessibility and standardization [23][25]. - 2026 is anticipated to be a pivotal year for validating the clinical value of UCAR-T, with several companies expected to release important clinical data [23][25]. - The balance of safety, durability, and accessibility will be central to the competitive landscape of CAR-T therapies, with UCAR-T providing a clearer risk-reward structure [25][26].

Core Insights - Bristol Myers Squibb (BMY) has received FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) to treat adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior lines of systemic therapy [1][11] Group 1: Product Approval and Market Position - Breyanzi is a CD19-directed CAR T cell therapy already approved for relapsed or refractory large B-cell lymphoma (LBCL) and has received accelerated approval for chronic lymphocytic leukemia and follicular lymphoma [2] - The latest FDA approval makes Breyanzi the only CAR T cell therapy approved for five different cancer types [3][11] - Breyanzi has also been approved in the EU for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy [3] Group 2: Sales Performance - Breyanzi sales surged 100% to $966 million in the first nine months of 2025, driven by strong growth in LBCL and new indications [4][11] - Sales in the U.S. are bolstered by the expansion into new approved indications, while international sales benefit from strong demand in existing and newly launched markets [4] Group 3: Competitive Landscape - Breyanzi faces competition from Gilead Sciences' Yescarta, which is also a CD19-directed CAR T cell therapy approved for similar indications [6][7] - Other competitors include Novartis' Kymriah, which has seen a 12% decline in sales to $296 million in the first nine months of 2025 [8] Group 4: Financial Performance and Valuation - BMY's shares have decreased by 8.2% year to date, contrasting with the industry's growth of 19.9% [10] - BMY is currently trading at a price/earnings ratio of 8.63x forward earnings, which is lower than the large-cap pharma industry's average of 16.95x [13]

Core Insights - Bristol Myers (BMY) is set to acquire Orbital Therapeutics for $1.5 billion in cash, enhancing its pipeline with OTX-201, a next-generation CAR T-cell therapy aimed at autoimmune diseases [1][11] - The acquisition will also incorporate Orbital's proprietary RNA platform, which focuses on durable and programmable RNA therapies [3][11] Company Pipeline and Products - OTX-201 is an investigational in vivo CAR T-cell therapy that utilizes the patient's own body to produce CAR T-cells, potentially reducing treatment burden and improving accessibility compared to traditional ex vivo therapies [2] - BMY's current cell therapy portfolio includes Breyanzi, a CD19-directed CAR T-cell therapy, which has shown significant sales growth of 125% to $344 million in Q2 2025 [4][6] - Breyanzi is approved for multiple indications, including relapsed or refractory large B-cell lymphoma and chronic lymphocytic leukemia [5] Competitive Landscape - BMY's cell therapies face competition from Gilead Sciences' Yescarta and Novartis' Kymriah, which are also approved for similar indications [7][9] - Yescarta reported sales of $393 million in Q2 2025, indicating strong market competition [9] Financial Performance and Valuation - BMY's shares have declined by 18.4% year-to-date, contrasting with the industry growth of 9.2% [12] - The company is trading at a price/earnings ratio of 7.19X forward earnings, which is below its historical mean of 8.45X and the large-cap pharma industry's average of 15.70X [13] - The bottom-line estimate for 2025 has increased slightly to $6.48, while the estimate for 2026 has decreased to $6.02 [14]

Core Insights - Bristol Myers' CAR T cell therapy Breyanzi demonstrated significant growth in Q2, with sales increasing by 125% to $344 million, driven by strong demand and new indication approvals [1][3][10] Group 1: Product Performance - Breyanzi is approved in the U.S. for treating relapsed or refractory large B-cell lymphoma (LBCL) and has received accelerated approval for chronic lymphocytic leukemia and follicular lymphoma [2] - U.S. sales of Breyanzi more than doubled year-over-year to $255 million, attributed to LBCL growth, new indications, and improved manufacturing success [3][10] - International sales nearly tripled to $88 million, reflecting strong demand and market expansion [3] Group 2: Future Outlook - Bristol Myers expects continued strong growth in the second half of 2025, with the FDA accepting a supplemental biologics license application for Breyanzi for treating relapsed or refractory marginal zone lymphoma [4] - The FDA has granted Priority Review for this application, with a target action date set for December 5, 2025 [4] Group 3: Competitive Landscape - Breyanzi faces competition from Gilead Sciences' Yescarta, which reported sales of $393 million in Q2 2025 [6][8] - Other competitors include Novartis' Kymriah, which is approved for acute lymphoblastic leukemia and LBCL [8] Group 4: Financial Performance and Valuation - Bristol Myers' shares have declined by 17.7% year-to-date, contrasting with a 0.9% decline in the industry [9] - The company is trading at a price/earnings ratio of 7.49x forward earnings, lower than its historical mean and the large-cap pharma industry's average of 13.73x [11] - The bottom-line estimate for 2025 has decreased to $6.46 from $6.56, while the estimate for 2026 has increased to $6.07 from $6.03 [12]

Core Insights - Novartis reported $14.05 billion in revenue for Q2 2025, a year-over-year increase of 9.2%, with an EPS of $2.42 compared to $1.97 a year ago, exceeding both revenue and EPS consensus estimates [1][3] Revenue Performance - Oncology revenue from Tasigna in the US was $162 million, significantly below the average estimate of $221.75 million, reflecting a year-over-year decline of 29.6% [4] - Net sales of Scemblix in the Rest of the World reached $107 million, surpassing the average estimate of $95.88 million [4] - Oncology revenue from Promacta/Revolade in the US was $227 million, below the average estimate of $285.63 million, marking a year-over-year decline of 19.8% [4] - Immunology revenue from Cosentyx in the US was $921 million, slightly below the average estimate of $993.18 million, but showing a year-over-year increase of 6.1% [4] - Total revenue from Tafinlar + Mekinist in Oncology was $573 million, slightly above the average estimate of $570.15 million, with a year-over-year increase of 9.6% [4] - Kisqali in Oncology generated $1.18 billion, exceeding the average estimate of $1.09 billion, with a substantial year-over-year increase of 64.2% [4] - Total revenue from Cosentyx in Immunology was $1.63 billion, below the average estimate of $1.73 billion, but reflecting a year-over-year increase of 6.8% [4] - Cardiovascular revenue from Entresto totaled $2.36 billion, slightly above the average estimate of $2.34 billion, with a year-over-year increase of 24.2% [4] - Established Brands revenue from Galvus Group was $123 million, below the average estimate of $131 million, reflecting a year-over-year decline of 18% [4] - Established Brands revenue from Exforge Group was $191 million, exceeding the average estimate of $172.31 million, with a year-over-year increase of 7.3% [4] - Kymriah in Established Brands generated $99 million, closely matching the average estimate of $99.32 million, with a year-over-year decline of 12.4% [4] Stock Performance - Novartis shares returned +2.1% over the past month, underperforming the Zacks S&P 500 composite's +4.2% change, with a Zacks Rank 2 (Buy) indicating potential for near-term outperformance [3]

Core Insights - Protara Therapeutics has appointed William "Bill" Conkling as Chief Commercial Officer, bringing over 20 years of experience in developing and commercializing therapies for cancer and rare diseases [1][2][3] - The company is positioned for growth with a potentially best-in-class bladder cancer therapy and two de-risked rare disease programs, aiming to significantly impact patient outcomes [2][5] Company Overview - Protara Therapeutics is a clinical-stage biotechnology company focused on transformative therapies for cancer and rare diseases, with its lead candidate TARA-002 in development for non-muscle invasive bladder cancer and lymphatic malformations [5] - The company is conducting ongoing Phase 2 trials for TARA-002 in patients with carcinoma in situ who are unresponsive or naïve to Bacillus Calmette-Guérin treatment, as well as in pediatric patients with lymphatic malformations [5] Leadership Background - Bill Conkling previously served as President and CEO of Rafael Holdings, where he built the commercial organization and developed go-to-market strategies [2][3] - He has extensive experience in the oncology field, having led the U.S. commercial organization for the launch of Trodelvy at Immunomedics and held key roles at Novartis Pharmaceuticals, including the commercialization of Kymriah [3][4] Stock Options and Awards - As part of his employment, Mr. Conkling received an inducement grant of options to purchase 200,000 shares at an exercise price of $3.30, along with a restricted stock unit award for 50,000 shares [6] - The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the following 36 months [6]

世界正迅速进入一个激动人心的医学新时代。曾经设计用于治疗数百万人的大型药物时代，正快速过渡到 个性化治疗的新纪元。依靠普适法则确保治疗方案适用于大多数受疗者，虽然惠及了无数人，但也使得许 多"非典型"患者无法获得有效的治疗解决方案——同时，支付方为无效治疗支付了大量资金。 在2021年，细胞和基因疗法（Cell and Gene Therapies, CGT）仅占全球药物市场总收入的0.8%。但随着超 过500种CGT进入研发状态，它们正准备在与传统技术的竞争中占据越来越大的市场份额。我们估计，全 球CGT市场将在2021年至2026年间以每年超过50%的年化增速增长，届时将有近200种疗法产生约570亿美 元的销售额，占全球药物市场的4%以上（见图1）。确实，CGT正逐步发展成为标准治疗的下一个浪潮， 瞄准一些现代社会中最常见的疾病，包括镰状细胞贫血、2型糖尿病和阿尔茨海默症。 美国FDA和其他监管机构已经批准了CGT（细胞与基因治疗）用于治疗冠状动脉疾病、遗传性视网膜病、 大B细胞淋巴瘤和脊髓性肌萎缩症等多种病理现象。 然而，最近的上市情况喜忧参半，公司在摸索前进时面临着未知的挑战，包括与往往百万美元的定 ...

As filed with the U.S. Securities and Exchange Commission on March 27, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant's name into English) 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 (Address, Including Zip Code, and Telephone Num ...